Canada Updates Medical Device Shortage Guidance in October 2026: Reporting Time Limits Move to Calendar Days from 17 June 2027

Canada Updates Medical Device Shortage Guidance in October 2026: Reporting Time Limits Move to Calendar Days from 17 June 2027

Published: 23 October 2026, 09:31 | Category: UDI, labelling and post-market surveillance

On 16 October 2026, Health Canada's Health Products Shortage Directorate issued a Medical Devices Compliance Program Bulletin explaining how the amendments in SOR/2026-96, published in Part II of the Canada Gazette on 17 June 2026, will be implemented, and simultaneously replaced two guidance documents. The bulletin divides the timetable into two stages: the exception importation and sale framework took effect on the date of publication; the new requirements for shortage and discontinuation reporting will apply from 17 June 2027. During the intervening year, the existing requirements remain in force.

Provisions already in force

The amendments include risk of harm to human health as one of the conditions for inclusion on the exception importation list; both actual and anticipated shortages can trigger it. Importers holding a medical device establishment licence must notify at least 3 working days before importing a device on the list. A more important new provision requires importers that receive or become aware of risk information notified in a foreign jurisdiction that may affect the safety or effectiveness of a listed device, such as a recall, to notify Health Canada.

Reporting changes

• The new rules require shortage information to be published directly on a designated website rather than submitted to Health Canada through the online form.
• The requirement to submit an explanation of how the shortage was discovered is removed.
• The exemption allowing a manufacturer not to report if it has an alternative device is removed.
• Time units change from working days to calendar days: 5 days means 5 calendar days, and deadlines no longer automatically extend over weekends.

Revised lead times

If an anticipated shortage is identified more than 6 months in advance, it must be reported at least 6 months before the expected start date; if it is expected to begin within 6 months, it must be reported within 5 calendar days after confirmation. The same applies to discontinuation: if the decision is made more than 12 months in advance, it must be reported at least 12 months before; if within 12 months, it must be reported within 5 calendar days after the decision. Changes to submitted information must be updated within 5 calendar days.

Two frequently overlooked points

First, all discontinuations of designated devices must be reported, regardless of whether a shortage is expected; an exemption applies only where a compatible alternative device is available to meet Canadian demand, among other circumstances. Second, a discontinuation report and the cancellation of a licence under section 43(3) of the Medical Devices Regulations are separate matters and cannot substitute for each other. There are also two categories of exemption: retailers and healthcare facility importers that distribute only within their own institution are not subject to shortage reporting obligations; and importers may report on behalf of manufacturers, for all device classes.

Guidance documents replaced

GUI-0137, Guide to reporting and providing information on medical device shortages and discontinuations, 4th edition, was published on 7 October 2026 and takes effect on 17 June 2027, replacing the 3rd edition of March 2022; until then, the current guidance continues to apply. The GUI-0147 guidance on exception importation and sale has also been revised. Health Canada scheduled an online information session for 21 October 2026.

Scope of application

GUI-0137 applies to manufacturers of Class I to IV devices and to importers of Class I devices; reporting obligations apply only to the categories on the designated devices list, not to all devices. The list is maintained and may be amended by Health Canada. Whether a product is in scope must be determined on the basis of the text of the list and the regulations, not on assumptions based on product classification.

Sources and verification

• Health Canada, Medical Devices Compliance Program Bulletin, Updated guidance documents on medical device shortages, 16 October 2026. https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/medical-devices-compliance-bulletin/updated-guidance-documents-medical-device-shortages.html
• Canada Gazette, Part II, Volume 160, Number 12, Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Shortages and Discontinuation of Sale of Drugs and Medical Devices), SOR/2026-96, published 17 June 2026. https://gazette.gc.ca/rp-pr/p2/2026/2026-06-17/html/sor-dors96-eng.html
• Health Canada, Guide to reporting and providing information on medical device shortages and discontinuations (GUI-0137), 4th edition, published 7 October 2026, effective 17 June 2027. https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/application-information/guidance-documents/guide-reporting-providing-information-medical-device-shortages-discontinuations-0137.html

Verification scope and access date: This review covered the full text of the above bulletin, the Canada Gazette amendment page and the GUI-0137 overview page, and checked the effective dates, reporting time limits, exemption scope and guidance version information. The access date was 23 October 2026.

Applicability note: This article interprets publicly available Canadian regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application, nor does it replace the original regulations and official guidance. The designated device list, reporting routes and time limits may change with subsequent official updates; actual application should be based on Health Canada's original texts and written responses.

AIMEILI Regulatory Interpretation

The most significant change is not the nominal shift from working days to calendar days, but the compression of practical response time and the expansion of reportable circumstances. A 5-calendar-day deadline can fall on a weekend or public holiday, so regulatory affairs teams need to treat the clock as continuous and ensure coverage outside standard business hours.

• Calendar-day compliance: weekend and holiday buffers disappear. A 5-day deadline may require decision-making, quality review and submission within a period that includes non-working days. Companies should define day zero, approval routes and backup approvers in advance.
• Foreign risk notification for exception imports: the new obligation creates a direct link between global vigilance intelligence and Canadian reporting. Recalls or safety notices in other jurisdictions must be assessed for listed devices and, where relevant, notified to Health Canada.
• Broader reporting population: removal of the alternative-device exemption and the requirement to report all designated-device discontinuations mean that supply continuity planning and regulatory reporting must be separated. A company may have a commercial alternative and still have a reporting obligation.
• Discontinuation is not licence cancellation: reporting a discontinuation does not satisfy, and is not replaced by, cancellation of a licence under section 43(3) of the Medical Devices Regulations.
• List-based scope: obligations depend on the designated devices list and the regulations, not on product classification alone. Product classification cannot be used as a proxy for determining reportability.

For regulatory affairs teams, GUI-0137 4th edition should be treated as the operative playbook from 17 June 2027, with the transition year used for gap assessment and procedure revision. The October 2026 bulletin and online information session provide implementation signals, but the regulations and the designated devices list remain the controlling references.

Business Impact

For global manufacturers, distributors, CROs and regulatory affairs teams, the amendments require changes to procedures, systems, contracts and training before 17 June 2027.

• Manufacturers: update shortage and discontinuation SOPs, report templates, decision trees and escalation matrices. Define day-zero triggers, build weekend and holiday coverage, assess all designated devices, and ensure that changes to submitted information can be updated within 5 calendar days.
• Importers and distributors: for exception imports, establish a 3-working-day pre-import notification process and a foreign recall and safety notice intake process. Clarify in contracts whether the importer will report on behalf of the manufacturer and for which device classes.
• Healthcare facility importers and retailers: confirm whether the own-institution distribution exemption applies and document the basis for that conclusion.
• CROs and regulatory service providers: incorporate calendar-day metrics into client procedures, training and mock audits. Validate that post-market surveillance and vigilance workflows capture foreign risk information that could affect listed devices, and map designated-device status for each product.
• Commercial and supply chain teams: align discontinuation decisions with the 12-month and 5-calendar-day reporting clocks. Do not rely on licence cancellation as a substitute for discontinuation reporting, and assess portfolio exposure to changes in the designated devices list.
• Documentation and training: update RA and QA training records, work instructions and system validations before 17 June 2027. Track the effective date of GUI-0137 4th edition, any GUI-0147 revisions and Health Canada list amendments.

Practical action before 17 June 2027: confirm each product's designated-device status, assign accountable roles for shortage and discontinuation reporting, test a 5-calendar-day escalation, and verify that foreign recall intelligence reaches the person responsible for Health Canada notifications for exception imports. Companies should retain evidence of the assessment and update it when Health Canada amends the list or guidance.